wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37026878-7994E244-19D2-4FF4-B3E3-FA85B4845533
Q37026878-7994E244-19D2-4FF4-B3E3-FA85B4845533
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37026878-7994E244-19D2-4FF4-B3E3-FA85B4845533
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
P2860
Q37026878-7994E244-19D2-4FF4-B3E3-FA85B4845533
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37026878-7994E244-19D2-4FF4-B3E3-FA85B4845533
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2c10c1500fbcc5ede57ffd5d8e5c5759d68a6a65
P2860
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.